Sugi Predict

Sugi Predict / Compounds / SCHEMBL1263942

SCHEMBL1263942

SCHEMBL1263942

CC(C)(C)OC(=O)N1CCc2ccc(Br)cc2CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.61
▸ NR1H2 P55055 1/20 0.60
▸ ABHD6 Q9BV23 4/20 0.53
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.45
▸ BACE1 P56817 2/20 0.44
▸ USP30 Q70CQ3 2/20 0.44
▸ RORC P51449 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL587847 0.92 ESR2 (0.74) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL1011003 0.92 NR1H2 (0.72) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL29587073 0.92 NR1H2 (0.72) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL29528794 0.92 ESR2 (0.74) ESR2NR1H2ABHD6NPC1RAB9A
Hydrochloric Acid SCHEMBL38653092 0.91 NR1H2 (0.70) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL31345278 0.91 ESR2 (0.57) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL5662155 0.86 ESR2 (0.53) ESR2NR1H2ABHD6NPC1RAB9A
SCHEMBL7868104 0.84 ESR2 (0.63) ESR2NR1H2NPC1RAB9AHDAC6
SCHEMBL2132877 0.84 ESR2 (0.84) ESR2NR1H2NPC1RAB9AUSP2
SCHEMBL24265586 0.84 NR1H2 (0.62) ESR2NR1H2ABHD6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114948963-B Benzolactam compounds as protein kinase inhibitors 大冢制药株式会社 2025-05-27 — — CN disclosed
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 — — US disclosed
EP-3601229-B1 TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS CALDAN THERAPEUTICS LTD (GB) 2024-11-06 — — EP disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 — — US disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 — — US disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 — — US disclosed
CN-110891938-B Tetrahydro-benzo [ D ] azepine derivatives as GPR120 modulators 卡尔丹治疗有限公司 2023-10-31 — — CN disclosed
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors ASCENEURON SA (CH) 2023-10-24 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 — — US disclosed
WO-2010151318-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 — — WO disclosed
WO-2010151318-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 — — WO disclosed
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof NORVARTIS AG 2010-01-28 — — US disclosed
EP-2120910-A2 HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF Novartis Ag (CH) 2009-11-25 — — EP disclosed
WO-2008076954-A2 HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2008-06-26 — — WO disclosed
US-7304050-B2 Antibacterial agents PFIZER INC. (US) 2007-12-04 — — US disclosed
US-7304050-B2 Antibacterial agents PFIZER INC. (US) 2007-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 ESR2 2187/4885NR1H2 1803/4885ABHD6 3830/4885
US-20110039827-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 ESR2 3443/4885NR1H2 818/4885ABHD6 4318/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ESR2 2188/4885NR1H2 1803/4885ABHD6 3817/4885
US-20240226115-A1 AXL INHIBITOR COMPOUNDS AXL, BTK, MERTK ESR2 1651/4885NR1H2 1621/4885ABHD6 3433/4885
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof HDAC1, HDAC3, HDAC10 ESR2 2057/4885NR1H2 327/4885ABHD6 1999/4885
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors BACE1, BACE2, BCHE ESR2 1696/4885NR1H2 856/4885ABHD6 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.